I confirm that the above details are correct:

Signed: ...... Date: .....

## HOSPITAL MEDICINES LIST RESTRICTIONS CHECKLIST

Use this checklist to determine if a patient meets the restrictions for funding in the **hospital setting**. For more details, refer to Section H of the Pharmaceutical Schedule. For community funding, see the Special Authority Criteria.

PRESCRIBER	PATIENT:
Name:	Name:
Ward:	NHI:
Ursodeoxycholic acid	
INITIATION – Alagille syndrome or progressive familial intrahepatic cholestasis  Prerequisites (tick boxes where appropriate)	
O Patient has been diagnosed with Alagille syndrome O Patient has progressive familial intrahepatic cholestasis	
INITIATION – Chronic severe drug induced cholestatic liver injury  Prerequisites (tick boxes where appropriate)	
O Patient has chronic severe drug induced cholestatic liver injury	
Cholestatic liver injury not due to Total Parenteral Nutrition (TPN) use in adults and	
Treatment with ursodeoxycholic acid may prevent hospital adr	nission or reduce duration of stay
INITIATION – Primary biliary cholangitis Prerequisites (tick boxes where appropriate)	
Primary biliary cholangitis confirmed by antimitochondrial antimit	
INITIATION – Pregnancy Prerequisites (tick box where appropriate)  Patient diagnosed with cholestasis of pregnancy	
INITIATION – Haematological transplant Prerequisites (tick boxes where appropriate)	
O Patient at risk of veno-occlusive disease or has hepatic impair cell or bone marrow transplantation and	ment and is undergoing conditioning treatment prior to allogenic stem
O Treatment for up to 13 weeks	
INITIATION – Total parenteral nutrition induced cholestasis Prerequisites (tick boxes where appropriate)	
O Paediatric patient has developed abnormal liver function as in and	dicated on testing which is likely to be induced by TPN
O Liver function has not improved with modifying the TPN comp	osition
INITIATION – prevention of sinusoidal obstruction syndrome Prerequisites (tick box where appropriate)	
The individual has leukaemia/lymphoma and requires prophylaxis for medications/therapies with a high risk of sinusoidal obstruction syndrome	